(Q37701381)

22 August 2017

1 reference

title

The use of antidepressants in clinical practice: focus on agomelatine (English)

1 reference

22 August 2017

author name string

R H McAllister-Williams

1

1 reference

22 August 2017

D S Baldwin

2

1 reference

22 August 2017

P M Haddad

3

1 reference

22 August 2017

S Bazire

4

1 reference

22 August 2017

publication date

1 March 2010

1 reference

22 August 2017

published in

Human Psychopharmacology

1 reference

22 August 2017

volume

25

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

95-102

1 reference

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

22 August 2017

cites work

1 reference

7 January 2021

Discontinuation symptoms in depression and anxiety disorders

1 reference

7 January 2021

Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis

1 reference

7 January 2021

The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats

1 reference

7 January 2021

Withdrawing patients from antidepressants

1 reference

7 January 2021

A neurotrophic model for stress-related mood disorders

1 reference

7 January 2021

Evidence of agomelatine's antidepressant efficacy: the key points

1 reference

7 January 2021

A review of the efficacy and tolerability of agomelatine in the treatment of major depression

1 reference

7 January 2021

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

1 reference

7 January 2021

Recognising and managing antidepressant discontinuation symptoms

1 reference

7 January 2021

Misdiagnosis of antidepressant discontinuation symptoms

1 reference

7 January 2021

Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain

1 reference

7 January 2021

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.

1 reference

7 January 2021

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

1 reference

7 January 2021

Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra.

1 reference

7 January 2021

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

1 reference

7 January 2021

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

1 reference

7 January 2021

Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine).

1 reference

7 January 2021

The hepatic safety profile of duloxetine: a review

1 reference

7 January 2021

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo

1 reference

7 January 2021

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

1 reference

7 January 2021

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

1 reference

7 January 2021

A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.

1 reference

7 January 2021

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

1 reference

7 January 2021

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

1 reference

7 January 2021

Effects of SSRIs on sexual function: a critical review

1 reference

7 January 2021

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

1 reference

7 January 2021

Human circadian rhythms: physiological and therapeutic relevance of light and melatonin

1 reference

7 January 2021

The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.1094

1 reference

22 August 2017

1 reference